The authors of this study determined the combined activity of venetoclax and FLT3-ITD inhibition in preclinical models of FLT3-ITD+ acute myeloid leukemia. They observed that FLT3-ITD inhibition combined with venetoclax had impressive anti-tumor activity and suggest that results of this study provide a strong mechanistic rationale for clinical studies.

In this study the gene expression profiles of β-thalassemia intermedia and major were analyzed by RNA sequencing. This approach identified sex differences suggesting that males and females are differentially affected by β-thalassemia. This finding highlights the need for considering sex as an important variable of the disease which should be considered when developing differential diagnostic and therapeutic strategies.